B2M / beta-2 microglobulin Antibody

B2M / beta-2 microglobulin Antibody Datasheet

B2M / beta-2 microglobulin Antibody Product Information

• Immunogen: Recombinant Human B2M / beta-2 microglobulin protein (Catalog#11976-H08H)
• Antibody Type: Rabbit Monoclonal Antibody ( Rabbit mAb Service Platform )
• Clone ID: 201
• Ig Type: Rabbit IgG
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was obtained from a rabbit immunized with purified, recombinant Human B2M / beta-2 microglobulin (rh B2M / beta-2 microglobulin; Catalog#11976-H08H; NP_004039.1; Met 1-Met 119).

B2M / beta-2 microglobulin Antibody Usage Guide

• Specificity: Human B2M / beta-2 microglobulin
• Western blot: This antibody can be used at 20-50 μg/mL with the appropriate secondary reagents to detect Human B2M in WB.

  A Sample (whole cell lysate) Hela Sample Volume (cells/lane) 2.5×105 Gel 13% SDS-PAGE reducing gel Recommended Concentration 20-50 μg/ml Secondary Antibody Dylight 800-Labeled Antibody To Rabbit IgG (H+L), at 1:5000 dilution.

• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

B2M / beta-2 microglobulin Antibody Background

Beta-2-microglobulin, also known as B2M, is a secreted protein which belongs to thebeta-2-microglobulin family. It contains oneIg-like C1-type (immunoglobulin-like) domain. Beta-2 microglobulin (B2M) plays a pivotal role in the biology of mammals, including its association with major histocompatibility complex (MHC) Class I gene products. The latter molecules have been shown to affect reproduction in both mice and humans. B2M forms the small invariable light chain subunit of class I HLA antigens on the cell membrane of all nucleated cells. During the continuous turnover of the HLA molecules. B2M is shed from the cell membrane into blood. Lymphocytes are the main source of serum free B2M. Serum B2M concentration is increased in renal diseases, various malignant diseases and some inflammatory and autoimmune disorders. In lymphatic malignancies serum B2M has significant prognostic value. B2M has been shown as a marker for monitoring inflammatory disease activity and it appears likely to have a destructive role in amyloidosis-related arthritis. B2M might be involved in the OA (osteoarthritis) pathogenesis. Defects in B2M are the cause of hypercatabolic hypoproteinemia. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation. B2M could be a potential therapeutic target in ovarian cancer.

References

1. Miyata T., et al.,1994 Biochemistry 33:12215-12221.
2. Remes,K. et al.,1996, Leuk Lymphoma21 (3-4): 233-8.
3. Trinh C.H., et al., 2002, Proc. Natl. Acad. Sci. USA. 99: 9771-9776.
4. He X.H., et al., 2004, Sheng Wu Gong Cheng Xue Bao 20: 99-103.
5. Kihara M., et al., 2006, J. Biol. Chem. 281: 31061-31069.
6. Ricagno S.,et al., 2009, Biochem.Biophys.Res.Commun. 380: 543-547.